Heart & blood pressure · Chicago area, IL
Heart and blood pressure studies in Chicago area, IL
73 recruiting studies have a site in the Chicago area. This page includes nearby cities such as Evanston, Oak Brook, Oak Lawn, Park Ridge.
73 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteers
BoxX-NoAF Clinical Trial
AtriCure, Inc.
- Location
- Chicago, IL + 30 other US sites
- Eligibility basics
- Ages 65+
- RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Pfizer
- Location
- Chicago, IL + 27 other US sites
- Eligibility basics
- Ages 18–79
- Recruiting
Prevail Global Study
Medtronic Vascular
- Location
- Chicago, IL + 53 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
AstraZeneca
- Location
- Champaign, IL + 151 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Novo Nordisk A/S
- Location
- Chicago, IL + 58 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
Boston Scientific Corporation
- Location
- Evanston, IL + 46 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
- Location
- Chicago, IL + 40 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 2
Transition to KPL-387 Monotherapy Dosing & Administration Study
Kiniksa Pharmaceuticals International, plc
- Location
- Chicago, IL + 20 other US sites
- Eligibility basics
- Ages 18–80
- Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
Supira Medical
- Location
- Chicago, IL + 24 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Alnylam Pharmaceuticals
- Location
- Chicago, IL + 213 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
Kardigan, Inc.
- Location
- Chicago, IL + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Boehringer Ingelheim
- Location
- Arlington Heights, IL + 91 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Boehringer Ingelheim
- Location
- Hazel Crest, IL + 78 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Boehringer Ingelheim
- Location
- Chicago, IL + 199 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
Liquidia Technologies, Inc.
- Location
- Chicago, IL + 12 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Gossamer Bio USA, Inc.
- Location
- Chicago, IL + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
AstraZeneca
- Location
- Chicago, IL + 93 other US sites
- Eligibility basics
- Ages 18–130
- RecruitingPhase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Cytokinetics
- Location
- Naperville, IL + 80 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Tempus AI
- Location
- Chicago, IL + 39 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
ELEVATE High-Risk PCI Pivotal Study
Magenta Medical Ltd.
- Location
- Chicago, IL + 32 other US sites
- Eligibility basics
- Ages 18–88
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Arlington Heights, IL + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Chicago, IL + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular…
Guerbet
- Location
- Evanston, IL
- Eligibility basics
- Ages 18+
- Recruiting
Zenith® Fenestrated+ Clinical Study
Cook Research Incorporated
- Location
- Chicago, IL + 29 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.